Daily Endocrinology Research Analysis
Analyzed 100 papers and selected 3 impactful papers.
Summary
Three impactful endocrinology studies stood out today: a multi-omic cohort defined histomolecular signatures of aggressiveness in pituitary neuroendocrine tumors; a longitudinal cohort linked prepubertal steroid metabolome, stress, and BMI to earlier pubertal onset in girls; and a large real-world cohort associated teprotumumab with increased long-term dysglycemia risk. Together, they advance molecular risk stratification, life-course endocrine epidemiology, and treatment safety monitoring.
Research Themes
- Molecular risk stratification in pituitary tumors via integrated multi-omics
- Steroid metabolome, stress, and adiposity shaping female pubertal timing
- Real-world endocrine therapy safety: teprotumumab-associated dysglycemia
Selected Articles
1. Genomic characterization of aggressiveness in pituitary neuroendocrine tumors (PitNETs).
In a 206-patient multi-omic study, aggressive PitNETs exhibited lineage-specific but convergent signatures combining a proliferative transcriptome with DNA hypermethylation. Alterations in LRP1B (novel for PitNET), TP53, and CDKN2A associated with aggressive features, whereas USP8/GNAS were not. Molecular signatures remained globally stable over disease course.
Impact: This work delivers a histomolecular definition of PitNET aggressiveness and implicates LRP1B as a novel gene, providing a framework for prognostic stratification beyond morphology.
Clinical Implications: Integrated molecular profiling could refine risk stratification, surveillance intensity, and adjuvant therapy decisions in PitNETs once prospectively validated.
Key Findings
- Aggressive PitNETs share a combined proliferative transcriptome and DNA hypermethylation signature across lineages.
- LRP1B, TP53, and CDKN2A alterations associate with aggressive features; USP8 and GNAS do not.
- Lineage-specific omic signatures overlap but remain distinct between corticotroph and mammo-somato-thyrotroph tumors.
- Molecular signatures remain globally stable during disease evolution despite potential clonal divergence.
Methodological Strengths
- Large, well-annotated cohort with integrated transcriptome, methylome, copy-number, and mutation data
- Lineage-specific analyses with cross-feature integration to derive convergent signatures
Limitations
- Observational design without prospective validation limits causal inference and clinical deployment
- Heterogeneity in prior treatments and centers may introduce confounding
Future Directions: Prospective multicenter validation of the aggressiveness signatures and development of clinically deployable assays to guide surveillance and adjuvant therapy trials.
BACKGROUND: Aggressive evolution of PitNETs is rare, metastatic spread even more. Defining aggressiveness and malignancy is challenging, subsequently hard to predict, and to understand. The aim was to provide a molecular definition of aggressiveness using genomic approaches. METHODS: PitNETs from 206 patients were included. Associations between 9 clinicopathological features of aggressiveness and PitNETs' omics were explored. Omics included transcriptome, DNA methylation, chromosomal alterations and mutations. Clonal tumor evolution was monitored in 7 patients. RESULTS: Among the 9 clinicopathological features of aggressiveness, only rapid progression, progression after radiotherapy, Ki67/MIB1 proliferation index ≥10%, temozolomide treatment, metastases and specific death were associated with specific omics signatures, while tumour maximal diameter ≥40mm, cavernous and sphenoid invasion were not. The omic signatures associated with these features of aggressiveness overlapped but remained distinct between corticotroph and mammo-somato-thyrotroph lineages. For each lineage, a common signature of aggressiveness was identified, associating proliferative transcriptome signature and DNA hypermethylation. Alterations in specific genes were associated with aggressive features, - including a novel PitNET gene, LRP1B, and known cancer genes (TP53, CDKN2A) -, while USP8 and GNAS alterations were not. Integration of gene alterations with methylome and transcriptome signatures isolated a subset of molecularly aggressive PitNETs. Molecular signatures were globally stable during the course of the disease, despite evolution towards aggressiveness and potential clonal divergence. CONCLUSION: This systematic analysis of clinicopathological features of aggressiveness using an integrated multiomic approach establishes a histomolecular definition of aggressiveness in PitNETs. Prospective cohorts studies are needed to validate these molecular signatures and establish their prognostic value.
2. Steroids, stress, and body mass index interact to accelerate female pubertal development.
In a 6-year longitudinal cohort (n=327), higher prepubertal urinary glucocorticoid, androgen, and progesterone metabolites were associated with earlier thelarche. High glucocorticoids combined with high BMI and stress advanced thelarche by approximately seven months compared with low-exposure peers.
Impact: It expands pubertal timing research beyond estrogens, identifying steroid metabolome-stress-BMI interactions as drivers of earlier thelarche with public health implications.
Clinical Implications: Risk identification and counseling may incorporate urinary steroid profiles and psychosocial context, supporting early lifestyle and stress interventions to mitigate early pubertal onset.
Key Findings
- Doubling of prepubertal glucocorticoid metabolites associated with earlier thelarche (HR 1.9, 95% CI 1.5-2.5).
- Doubling of prepubertal androgen metabolites associated with earlier thelarche (HR 3.9, 95% CI 2.7-5.6).
- Doubling of prepubertal progesterone metabolites associated with earlier thelarche (HR 6.7, 95% CI 4.1-10.9).
- Combined high glucocorticoids, BMI, and stress advanced thelarche by about seven months.
Methodological Strengths
- Prospective longitudinal design with 6-year follow-up and repeated urinary steroid metabolomics
- Use of Weibull survival models testing interactions with BMI z-scores and stress proxies
Limitations
- Parental report of thelarche timing, although correlated with clinical Tanner staging, may introduce measurement error
- Generalizability may be limited and residual confounding cannot be excluded
Future Directions: Validate findings in diverse populations; test whether targeted stress reduction and weight management modify steroid profiles and pubertal timing.
CONTEXT: Estrogens underlie puberty in girls, but the steroid metabolome may also regulate pubertal timing in response to elevated stress and increasing body mass index (BMI). OBJECTIVE: Our objective was to identify steroid metabolome patterns linked to accelerated puberty and test whether BMI and stress markers modify this relationship. METHODS: From the LEGACY Girls Study, a longitudinal cohort followed for 6 years, we selected 327 girls aged 5 to 13 years at baseline to measure 36 steroid metabolites of glucocorticoids, androgens, progesterone, and estrogens in 2 urine samples collected before and during puberty. Parents reported the age at onset of breast development (thelarche), which had a high correlation in the subset with clinically assessed Tanner. Study staff measured height and weight and administered questionnaires, including the Internalizing Composite Scale, a parental proxy of child stress. We estimated hazard ratios (HRs) for the association between doubled steroid metabolites and ages at thelarche, pubarche, and menarche using Weibull survival models, testing interactions with stress and BMI z-scores. RESULTS: Accelerated thelarche was associated with higher prepubertal urinary metabolites of glucocorticoids (HR = 1.9, 95% CI: 1.5-2.5), androgens (HR = 3.9, 95% CI: 2.7-5.6), and progesterone (HR = 6.7, 95% CI: 4.1-10.9). Girls with high glucocorticoid metabolites combined with high BMI and stress reached thelarche 7 months earlier than their counterparts with low measures in these parameters. CONCLUSION: Elevated metabolites of glucocorticoids, androgens, and progesterone are associated with accelerated pubertal onset, and BMI and stress modify this association. Previous studies have focused on estrogens, menarche, and BMI; our results suggest that androgens and stress impact the timing of thelarche as well, explaining secular declines in pubertal timing.
3. Teprotumumab-Associated Hyperglycemia: A Large-Scale Multinational Cohort Study.
Across 792 propensity-matched pairs with up to 5 years of follow-up, teprotumumab increased risks of prediabetes (HR 2.03), incident diabetes (HR 2.23), and initiation of antidiabetes medications (HR 1.68). Absolute risk increases were modest, supporting routine glucose monitoring and individualized risk–benefit discussions.
Impact: Provides the largest real-world quantification of dysglycemia risk with teprotumumab, informing safety monitoring and shared decision-making in TED treatment.
Clinical Implications: Baseline glycemic assessment and ongoing monitoring during and after therapy should be standard; anticipate and manage dysglycemia proactively, especially in patients with metabolic risk.
Key Findings
- Teprotumumab increased 5-year prediabetes risk (HR 2.03; 24% vs 10% in controls).
- Incident diabetes risk at 5 years was higher with teprotumumab (HR 2.23).
- Greater likelihood of initiating antidiabetes medications by 5 years (HR 1.68).
Methodological Strengths
- Large, multinational EHR network with propensity score matching to balance baseline risk
- Time-to-event analyses over extended follow-up (up to 5 years) with multiple glycemic outcomes
Limitations
- Observational design susceptible to residual confounding and misclassification in EHRs
- Lack of detailed dosing/timing and standardized glucose testing protocols
Future Directions: Prospective studies to identify high-risk subgroups, define monitoring intervals, and test mitigation strategies for dysglycemia during IGF-1R inhibition.
OBJECTIVE: Teprotumumab, a monoclonal antibody targeting the insulin-like growth factor-1 receptor, represents the first Food and Drug Administration (FDA)-approved treatment for thyroid eye disease (TED). However, hyperglycemia has emerged as a significant adverse event, with limited real-world data on its incidence and clinical impact. This study aimed to evaluate the risk of glycemic abnormalities associated with teprotumumab treatment using a large, multinational electronic health records database. METHODS: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, which includes data from more than 165 health care organizations worldwide. Patients with TED treated with teprotumumab were matched 11 to TED patients who did not receive teprotumumab using propensity score matching (PSM). The primary outcomes were incident prediabetes, diabetes, hyperglycemia defined by a random blood glucose level ≥200 mg/dL, and initiation of antidiabetes medications during follow-up ranging from 6 months to 5 years. Time-to-event analyses were performed using Kaplan-Meier survival curves to estimate cumulative incidence over time. RESULTS: After PSM, 792 teprotumumab-treated patients were compared with 792 matched controls over a follow-up period of up to 5 years. Teprotumumab treatment was associated with a significantly increased risk of prediabetes at 5 years (HR: 2.03, CI: 1.51-2.72), affecting 24% of treated patients compared with 10% of controls. The risk of incident diabetes at 5 years was also significantly higher in the teprotumumab-treated patients (HR: 2.23, CI: 1.46-3.43). Teprotumumab-treated patients were more likely to require the addition of antidiabetes medications at 5 years (HR: 1.68, CI: 1.27-2.22). CONCLUSIONS: In this large-scale cohort study, teprotumumab treatment was associated with an increased risk of dysglycemia. Although this risk was observed across several glycemic outcomes, the absolute risk increase was modest. These findings support routine glucose monitoring and proactive glycemic management, while emphasizing the importance of individualized risk-benefit assessment when considering teprotumumab therapy in patients with TED.